Hospital General Universitario Gregorio Marañón

Running trials

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· University of Oxford· Source

• Not yet recruiting

  Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)

  NCT07679646· Air Liquide Healthcare Spain· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Systimmune Inc.· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer

  2025-523276-23-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· University of Oxford· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

  2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Not yet recruiting

  A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

  2026-525964-17-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Not yet recruiting

  Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma

  2026-525703-27-00· Phase 4· Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz· Source

• Not yet recruiting

  UNLOAD-CHF Urea for Normalizing hyponatremia and reducing voLume Overload in Acute and Chronic Heart Failure

  2025-523981-26-03· Phase 3· Nutricion Medica S.L.· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

  NCT07247162· Phase 4· RECORDATI GROUP· Source

• Recruiting

  A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

  NCT07460986· Phase 1/2· MedSIR· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· BeOne Medicines I GmbH· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

  2025-524816-13-00· Phase 2· Janssen Cilag International· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· AbbVie· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Phase 3· Pfizer· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Recruiting

  An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

  NCT07620392· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

  NCT07018947· Phase 2· Fundacion Clinic per a la Recerca Biomédica· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS

  2025-523396-38-00· Phase 1/2· Aop Orphan Pharmaceuticals GmbH· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

Showing 50 of 538.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer45 recruiting
• Childhood cancers27 recruiting
• Colorectal cancer25 recruiting
• Pancreatic cancer19 recruiting
• Gastric and oesophageal cancer17 recruiting
• Metastatic breast cancer16 recruiting
• Liver and biliary tract cancer14 recruiting
• Fatty liver disease (MASLD/MASH)12 recruiting
• Ovarian cancer11 recruiting
• Acute myeloid leukaemia10 recruiting
• Melanoma10 recruiting
• Multiple myeloma10 recruiting
• Sarcoma10 recruiting
• Bladder cancer9 recruiting
• Heart failure8 recruiting
• Multiple sclerosis7 recruiting
• Prostate cancer7 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Obesity6 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Head and neck cancer5 recruiting
• Liver cirrhosis5 recruiting
• Mantle cell lymphoma5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• COPD4 recruiting
• Hodgkin lymphoma4 recruiting
• Immune thrombocytopenia (ITP)4 recruiting
• Kidney cancer4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Neuroendocrine tumours4 recruiting
• Triple-negative breast cancer4 recruiting
• Crohn's disease3 recruiting
• Endometrial cancer3 recruiting
• Follicular lymphoma3 recruiting
• Rheumatoid arthritis3 recruiting
• Schizophrenia3 recruiting
• Sickle cell disease3 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• Atrial fibrillation2 recruiting
• Bronchiectasis2 recruiting
• Cervical cancer2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Depression2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lupus (SLE)2 recruiting
• Psoriatic arthritis2 recruiting
• Ankylosing spondylitis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bipolar disorder1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Congenital heart disease1 recruiting
• Coronary artery disease1 recruiting
• Cushing's syndrome1 recruiting
• Cystic fibrosis1 recruiting
• Cytomegalovirus infection1 recruiting
• Dilated cardiomyopathy1 recruiting
• Glioblastoma1 recruiting
• Hidradenitis suppurativa1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Irritable bowel syndrome1 recruiting
• Myocarditis1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Terminated

  Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  NCT07061080· Phase 2· Grupo Espanol de Tumores Neuroendocrinos· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Active, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Active, not recruiting

  Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)

  2024-517818-15-00· Phase 1/2· Merck Healthcare KGaA· Source

• Completed

  A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs

  NCT06599502· Phase 1/2· AstraZeneca AB· Source

• Completed

  Artificial Intelligence Scalable Solution for ST Myocardial Infarction

  NCT06939738· Idoven 1903 S.L.· Source

• Completed

  An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

  2024-512670-10-00· Phase 1/2· BioInvent International AB· Source

• Completed

  KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

  NCT05846516· Phase 1· Boehringer Ingelheim International GmbH· Source

• Terminated

  A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT06685835· Phase 2· Insmed Incorporated· Source

• Completed

  An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma

  2024-511949-19-00· Phase 1· Sairopa B.V.· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06542874· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

  2023-508819-23-00· Phase 1· Hutchmed Ltd.· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Faes Farma S.A.· Source

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Janssen Cilag International· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease.

  2023-506432-32-00· Phase 4· Bellvitge University Hospital· Source

• Completed

  A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

  NCT06131372· Phase 2· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Upstream Bio Inc.· Source

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Incyte Corporation· Source

• Completed

  Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.

  2022-502413-29-00· Phase 2· Asociacion Grupo Tratamiento De Tumores Digestivos· Source

• Terminated

  Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

  NCT05999968· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Sanofi· Source

• Completed

  Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors

  NCT06024174· Phase 1/2· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Shionogi Inc.· Source

• Active, not recruiting

  A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

  NCT05835986· Phase 1· Hoffmann-La Roche· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Boehringer Ingelheim· Source

• Completed

  CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax

  2023-505828-58-00· Phase 1· Curis Inc.· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatectomy

  NCT06055946· Aesculap AG· Source

• Completed

  A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

  2022-503108-26-00· Phase 1/2· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD

  2022-502274-16-00· Phase 4· AstraZeneca AB· Source

Showing 50 of 284.

Conditions

Diseases this institution publishes on or runs trials for.

• Schizophrenia54 works · 3 trials
• Sarcoma22 works · 18 trials
• Lupus (SLE)21 works · 10 trials
• Hepatitis C15 works · 0 trials
• Diffuse large B-cell lymphoma12 works · 14 trials
• Metastatic breast cancer12 works · 45 trials
• Immune thrombocytopenia (ITP)10 works · 13 trials
• Myocarditis10 works · 1 trial
• Cushing's syndrome9 works · 2 trials
• Psoriatic arthritis8 works · 3 trials
• Dystonia7 works · 0 trials
• Dermatomyositis and polymyositis (myositis)5 works · 3 trials
• Mantle cell lymphoma4 works · 10 trials
• Fabry disease3 works · 2 trials